Evaluation of the In Vitro Antimicrobial Efficacy Against Staphylococcus aureus and epidermidis of a Novel 3D-Printed Degradable Drug Delivery System Based on Polycaprolactone/ Chitosan/ Vancomycin. Preclinical Study
Authors:
- Iván López-GonzálezILIván López-González
- Ana Belén Hernández-HerediaAna Belén Hernández-Heredia
- María Isabel Rodríguez-LópezMRMaría Isabel Rodríguez-López
- David Auñón-CallesDADavid Auñón-Calles
- Mohamed BoudifaMBMohamed Boudifa
- José Antonio GabaldónJosé Antonio Gabaldón
- Luis Meseguer-OlmoLMLuis Meseguer-Olmo
Preprint
- 9 May 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Acute and chronic bone infections, especially those caused by methicillin-resistant Staphylococcus aureus (MRSA), remains a major complication and therapeutic challenge. It is documented that local administration of vancomycin offers better results than the usual routes of administration (e.g. intravenous) when ischemic areas are present. In this work, we evaluate the antimicrobial efficacy against S. aureus and S. epidermidis and analyzed the potential cytotoxic effect of a novel hybrid 3D-printed scaffold based on poly(caprolactone) and chitosan loaded with different vancomycin concentrations (1, 5, 10 and 20%). For this purpose, vancomycin release was measured by means of HPLC, and the biological response of ah-BM-MSCs in the presence of the scaffolds was evaluated in terms of cytotoxicity (LDH activity), proliferation (AlamarBlueⓇ) and osteogenic differentiation (ALP activity, Alizarin Red staining). In addition, two cold plasma treatments were evaluated to improve the adhesion of hydrophobic polymers to hydrogels. The hybrid PCL/CS/Van scaffolds tested were found to be biocompatible, bioactive, and bactericide, as demonstrated by no cytotoxicity or functional alteration and by bacterial inhibition. Our results suggest that the scaffolds developed would be excellent candidates to be used in a wide range of biomedical fields such as drug delivery systems or tissue engineering applications.Keywords
All Related Versions
- Version 1, 2023-05-09, Preprints
- Published version: Pharmaceutics, 15 (6), 1763.